bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

 
  Other news for:
Lymphoma
Neoplasms
Lupus
 Resources from HONselect
No Evidence That Lupus Drugs Lead to Cancer, Says Study
Concerns that cyclophosphamide, other meds raise lymphoma risk not borne out by research

By Robert Preidt

MONDAY, Feb. 4 (HealthDay News) -- Drugs used to treat the autoimmune disease lupus do not significantly increase patients' risk of the blood cancer lymphoma, a new study says.

The findings should help reduce widely held fears about a link between lupus medication and lymphoma, said the researchers at McGill University in Montreal.

In people with systemic lupus erythematosus (SLE), the immune system attacks healthy tissue such as the skin, joints, kidneys and the brain. Medications to suppress the immune system are used to treat lupus, but previous research has suggested that this may put patients at increased risk for lymphoma.

Because of fears about developing cancer, some lupus patients are reluctant to take their medication, and others stop taking it.

This international study included 75 lupus patients who had lymphoma and nearly 5,000 cancer-free lupus patients. Researchers looked at most of the drugs commonly used to treat lupus, including cyclophosphamide, which is used only for severe lupus cases.

The researchers concluded that the risk of lymphoma in lupus patients who took cyclophosphamide was less than 0.1 percent per year. In addition, there was no link between lupus disease activity and lymphoma risk, according to the study recently published in the journal Annals of the Rheumatic Diseases.

"People have been wondering for a long time whether the medications were to blame and the results are reassuring, suggesting that most lymphoma cases in SLE are not triggered by drug exposures," first and corresponding author Dr. Sasha Bernatsky, a researcher in the divisions of clinical epidemiology and rheumatology at the Research Institute of the McGill University Health Center, said in a university news release.

Future research will look at how lupus patients' genetics might influence the interaction between medication and lymphoma risk.

More information

The U.S. National Institute of Arthritis and Musculoskeletal Diseases has more about lupus.

SOURCE: McGill University, news release, Jan. 24, 2013

Health News Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=672917

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Lymphoma
Neoplasms
Specialty Chemicals and Products
Lead
Risk
Research Personnel
Cyclophosphamide
Immune System
Fear
Lupus Erythematosus, Systemic
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact